CA3199594A1 - Antibodies against sars-cov-2 and uses thereof - Google Patents

Antibodies against sars-cov-2 and uses thereof

Info

Publication number
CA3199594A1
CA3199594A1 CA3199594A CA3199594A CA3199594A1 CA 3199594 A1 CA3199594 A1 CA 3199594A1 CA 3199594 A CA3199594 A CA 3199594A CA 3199594 A CA3199594 A CA 3199594A CA 3199594 A1 CA3199594 A1 CA 3199594A1
Authority
CA
Canada
Prior art keywords
yang
antibody
impi
domain
cdrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3199594A
Other languages
English (en)
French (fr)
Inventor
Paul Kellam
Anne PALSER
Volker Germaschewski
Simon James Watson
Benjamin David Grimshaw
Spela Binter
Jaroslaw Michal SZARY
Margot BILLAUD
Robert Rowlands
Aishwarya KRISHNA
Huan-chun LIN
Cheng-yuan YANG
Li-Ying LIOU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Publication of CA3199594A1 publication Critical patent/CA3199594A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pulmonology (AREA)
CA3199594A 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof Pending CA3199594A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2017058.5 2020-10-27
GBGB2017058.5A GB202017058D0 (en) 2020-10-27 2020-10-27 Antibodies and uses thereof
PCT/EP2021/079901 WO2022090353A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Publications (1)

Publication Number Publication Date
CA3199594A1 true CA3199594A1 (en) 2022-05-05

Family

ID=73727037

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3199594A Pending CA3199594A1 (en) 2020-10-27 2021-10-27 Antibodies against sars-cov-2 and uses thereof

Country Status (12)

Country Link
US (1) US20250026813A1 (https=)
EP (1) EP4237442A1 (https=)
JP (1) JP2023549067A (https=)
KR (1) KR20230113295A (https=)
CN (1) CN117396501A (https=)
AU (1) AU2021369450A1 (https=)
CA (1) CA3199594A1 (https=)
CO (1) CO2023006684A2 (https=)
GB (1) GB202017058D0 (https=)
IL (1) IL302244A (https=)
MX (1) MX2023004869A (https=)
WO (1) WO2022090353A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
FI20215508A1 (en) 2020-04-09 2021-10-10 Niemelae Erik Johan Mimetic nanoparticles to prevent the spread of new coronaviruses and reduce the rate of infection
BR112022024662A2 (pt) 2020-06-03 2023-04-04 Regeneron Pharma Métodos para tratamento ou prevenção de infecções por sars-cov-2 e covid-19 com anticorpos de glicoproteína spike anti-sars-cov-2
CN114989263B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-N及其制备方法与应用
CN114989255B (zh) * 2021-03-01 2023-07-25 中国医学科学院基础医学研究所 与SARS-CoV-2刺突蛋白特异性结合的多肽KVp-R及其制备方法与应用
US12496470B2 (en) 2021-07-14 2025-12-16 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
EP4630447A2 (en) * 2022-12-09 2025-10-15 Abwiz Bio, Inc. Antibodies or fragments thereof for sars-cov-2 and variants thereof
EP4649096A2 (en) * 2023-01-10 2025-11-19 Sana Biotechnology, Inc. Cd19-specific antibody constructs and compositions thereof
KR20250016745A (ko) * 2023-07-25 2025-02-04 연세대학교 산학협력단 신규한 펩타이드, 이를 포함하는 항체 또는 이의 항원 결합 단편, 이를 포함하는 SARS-CoV-2 검출용 물질

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
CA2109528A1 (en) 1991-05-01 1992-11-02 Gregory A. Prince A method for treating infectious respiratory diseases
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
CA2277801C (en) 1997-01-16 2002-10-15 Massachusetts Institute Of Technology Preparation of particles for inhalation
WO1999066903A2 (en) 1998-06-24 1999-12-29 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof

Also Published As

Publication number Publication date
WO2022090353A1 (en) 2022-05-05
JP2023549067A (ja) 2023-11-22
KR20230113295A (ko) 2023-07-28
MX2023004869A (es) 2023-06-01
CO2023006684A2 (es) 2023-05-29
AU2021369450A1 (en) 2023-06-22
AU2021369450A9 (en) 2025-04-10
US20250026813A1 (en) 2025-01-23
IL302244A (en) 2023-06-01
GB202017058D0 (en) 2020-12-09
CN117396501A (zh) 2024-01-12
EP4237442A1 (en) 2023-09-06

Similar Documents

Publication Publication Date Title
CA3199594A1 (en) Antibodies against sars-cov-2 and uses thereof
JP2020120683A (ja) エボラウイルス糖タンパク質に対するヒト抗体
US20240336691A1 (en) Anti-tl1a antibody compositions and methods of treatment in the lung
TWI613214B (zh) 抗血球凝集素抗體及使用方法
JP2019055996A (ja) インフルエンザ赤血球凝集素に対するヒト抗体
JP2023528072A (ja) ＳＡＲＳ－ＣｏＶ－２糖タンパク質Ｓに対する中和活性を有する治療用抗体
JP7463366B2 (ja) 新規の抗ジカウイルス抗体及びその使用
WO2023133538A2 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and il23 inhibitors
US20230257449A1 (en) Compositions and methods for treating and preventing influenza
CN111670195B (zh) 针对流感血凝素的人抗体
CN120917045A (zh) 治疗皮肤的抗tl1a抗体组合物和方法
EP4585687A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
WO2024148222A1 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and integrin inhibitors
EP4646434A2 (en) Methods of treating inflammatory diseases with combination of tl1a inhibitors and tnf inhibitors
WO2022164805A9 (en) Compositions and methods for treating hepatitis b virus infection
EP4208479A1 (en) Human monoclonal antibodies to sars-cov-2 and use thereof
WO2022162097A2 (en) Antibodies and uses thereof
US20240209065A1 (en) Secretory iga antibodies against covid infection
WO2025184137A1 (en) Influenza antibodies and methods of use thereof
WO2024120516A1 (zh) 特异性结合rsv的抗体
IT202300015579A1 (it) Anticorpi contro covid-19 e altri coronavirus umani
CN116916958A (zh) 用于sars-cov-2感染的抗体疗法
HK40111253A (zh) 抗pacap抗体的组合物和方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241004

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241004

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251215